# MCE MedChemExpress

### **Product** Data Sheet

## Dipyridamole-d<sub>20</sub>

 $\begin{tabular}{llll} \textbf{Cat. No.:} & HY-B0312S \\ \begin{tabular}{llll} \textbf{CAS No.:} & 1189983-52-5 \\ \begin{tabular}{llll} \textbf{Molecular Formula:} & $C_{24}H_{20}D_{20}N_8O_4 \\ \end{tabular} \label{eq:cat.No.:} \end{tabular}$ 

Molecular Weight: 524.75

Target: Phosphodiesterase (PDE)
Pathway: Metabolic Enzyme/Protease

Storage: Powder -20°C 3 years

In solvent

4°C 2 years -80°C 6 months

-20°C 1 month

#### **SOLVENT & SOLUBILITY**

In Vitro DMSO : ≥ 50 mg/mL (95.28 mM)

H2O: 0.67 mg/mL (1.28 mM; Need ultrasonic)
\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.9057 mL	9.5283 mL	19.0567 mL
	5 mM	0.3811 mL	1.9057 mL	3.8113 mL
	10 mM	0.1906 mL	0.9528 mL	1.9057 mL

Please refer to the solubility information to select the appropriate solvent.

#### **BIOLOGICAL ACTIVITY**

Description	Dipyridamole-d <sub>20</sub> is the deuterium labeled Dipyridamole. Dipyridamole is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells[1][2][3].
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **REFERENCES**

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.



Page 2 of 2 www.MedChemExpress.com